These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32616682)

  • 1. Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study.
    Chung JW; Choi HY; Ki M; Jang ES; Jeong SH
    Gut Liver; 2021 Mar; 15(2):295-306. PubMed ID: 32616682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comorbidities and the use of comedications among patients with chronic hepatitis C in Korea: A nationwide cross-sectional study.
    Kwon KM; Shim JJ; Kim GA; Kim BO; Han H; Ahn HJ
    Korean J Intern Med; 2023 May; 38(3):338-348. PubMed ID: 37032119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.
    Hudson B; Walker AJ; Irving WL
    J Med Virol; 2017 Dec; 89(12):2158-2164. PubMed ID: 28480974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    Kondili LA; Gaeta GB; Ieluzzi D; Zignego AL; Monti M; Gori A; Soria A; Raimondo G; Filomia R; Di Leo A; Iannone A; Massari M; Corsini R; Gulminetti R; Gatti Comini A; Toniutto P; Dissegna D; Russo FP; Zanetto A; Rumi MG; Brancaccio G; Danieli E; Brunetto MR; Weimer LE; Quaranta MG; Vella S; Puoti M
    PLoS One; 2017; 12(2):e0172159. PubMed ID: 28245248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016.
    Ruzicka DJ; Tetsuka J; Fujimoto G; Kanto T
    BMC Infect Dis; 2018 May; 18(1):237. PubMed ID: 29793436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain.
    Sicras Mainar A; Navarro Artieda R; Hernández I; Morillo R
    Gastroenterol Hepatol; 2019 Oct; 42(8):465-475. PubMed ID: 31451229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comorbidities and concomitant medications in patients with chronic hepatitis C virus infection receiving second-generation direct-acting antiviral regimens in Belgium: an observational study.
    Bourgeois S; Mulkay JP; Cool M; Verhelst X; Robaeys G; Lasser L; Lefebvre V; Colle I; Van Steenkiste C; Decaestecker J; Coulon S; Venken K; Vanwolleghem T
    Acta Gastroenterol Belg; 2021; 84(1):33-41. PubMed ID: 33639691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.
    Liu CH; Yu ML; Peng CY; Hsieh TY; Huang YH; Su WW; Cheng PN; Lin CL; Lo CC; Chen CY; Chen JJ; Ma Q; Brooks-Rooney C; Kao JH
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1290-1300. PubMed ID: 30362139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.
    Lauffenburger JC; Mayer CL; Hawke RL; Brouwer KL; Fried MW; Farley JF
    Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1073-82. PubMed ID: 25014625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers.
    Lam L; Fontaine H; Lapidus N; Dorival C; Bellet J; Larrey D; Nahon P; Diallo A; Cagnot C; Lusivika-Nzinga C; Téoulé F; Hejblum G; Bourlière M; Pol S; Carrat F;
    Pharmacoepidemiol Drug Saf; 2023 Apr; 32(4):486-495. PubMed ID: 36444965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comorbidities and concomitant medication use in adult patients with chronic hepatitis C: a descriptive epidemiological analysis].
    Wang Q; Rao HY; Yu N; Gao SQ; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):225-232. PubMed ID: 29804396
    [No Abstract]   [Full Text] [Related]  

  • 12. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
    Dhiman RK; Grover GS; Premkumar M; Taneja S; Duseja A; Arora S; Rathi S; Satsangi S; Roy A;
    J Hepatol; 2019 Dec; 71(6):1076-1085. PubMed ID: 31325468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.
    Aas CF; Vold JH; Skurtveit S; Odsbu I; Chalabianloo F; Lim AG; Johansson KA; Fadnes LT
    Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):44. PubMed ID: 32605625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan.
    Chen JH; Wu PN; Huang SC; Hsu PJ; Hsu JC
    Curr Med Res Opin; 2021 Feb; 37(2):245-252. PubMed ID: 33251875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden.
    Büsch K; Waldenström J; Lagging M; Aleman S; Weiland O; Kövamees J; Duberg AS; Söderholm J
    Scand J Gastroenterol; 2017 Jan; 52(1):61-68. PubMed ID: 27598393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.
    Hsu PY; Wei YJ; Lee JJ; Niu SW; Huang JC; Hsu CT; Jang TY; Yeh ML; Huang CI; Liang PC; Lin YH; Hsieh MY; Hsieh MH; Chen SC; Dai CY; Lin ZY; Chen SC; Huang JF; Chang JM; Hwang SJ; Chuang WL; Huang CF; Chiu YW; Yu ML
    Clin Mol Hepatol; 2021 Jan; 27(1):186-196. PubMed ID: 33317251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
    Yu JH; Lee JI; Lee KS; Kim JK
    Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims' Data.
    Ki M; Choi HY; Kim KA; Jang ES; Jeong SH
    Gut Liver; 2017 Nov; 11(6):835-842. PubMed ID: 28798283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study.
    Nam JY; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Bae SH; Ki M; Choi HY; Lee EY; Jeong SH
    Gut Liver; 2020 Mar; 14(2):207-217. PubMed ID: 31158950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.